<p>Maxim Group 分析师 Naz Rahman 重申了对 KZIA 股票的看涨态度，今天给予了买入评级。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁可信赖的数据驱动投资工具，使用 TipRanks Premium，从分析师评级和预测到最新消息和投资组合分析。</li>
<li>通过 TipRanks 智能投资者通讯发现高信心的股票推荐和新的投资机会。</li>
</ul>
<p>Naz Rahman 给予买入评级是基于与 paxalisib 相关的临床和市场背景的多种因素。他认为 Celcuity 在其 PI3K/mTOR 抑制剂的 III 期结果具有统计学显著性，这增强了对整个类别的信心，并进一步验证了 Kazia 采用的口服 PI3K/AKT/mTOR 药物的有效性，该药物在耐受性方面表现出令人鼓舞的结果，而没有一些静脉给药方案中观察到的高中性粒细胞减少率。</p>
<p>Rahman 还指出，Celcuity 即将到来的 PDUFA 决策以及 PI3K/mTOR 领域日益增长的交易活动表明该路径中高质量资产的战略价值正在上升。随着 Kazia 扩大其三阴性乳腺癌试验以及更广泛的机制进一步降低风险，他降低了对 paxalisib 的收入风险假设，并将其 12 个月的目标价提高至 30 美元，进一步巩固了对该股票的买入推荐。</p>
<p>在今天发布的另一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价为 18.00 美元。</p>

KZIA

CELC

<p>Maxim Group 分析师 Naz Rahman 重申了对 Kazia Therapeutics (KZIA) 的买入评级，将 12 个月的目标价提高至 30 美元。此次评级上调反映了对 Kazia 的 PI3K/AKT/mTOR 战略的信心增强，得益于 Celcuity 积极的三期临床试验结果和降低风险的机制。此外，H.C. Wainwright 维持了买入评级，目标价为 18 美元</p>

<p>Maxim Group analyst Naz Rahman has reiterated their bullish stance on KZIA stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>Maxim Group 分析师 Naz Rahman 重申了对 KZIA 股票的看涨态度，今天给予了买入评级。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.</li>
<li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁可信赖的数据驱动投资工具，使用 TipRanks Premium，从分析师评级和预测到最新消息和投资组合分析。</li>
<li>通过 TipRanks 智能投资者通讯发现高信心的股票推荐和新的投资机会。</li>
</ul>
</div><p>Naz Rahman has given his Buy rating due to a combination of factors relating to both the clinical and market backdrop for paxalisib. He sees Celcuity’s statistically significant Phase 3 results with its PI3K/mTOR inhibitor as strengthening confidence in the entire class, and by extension validating Kazia’s approach with an orally administered PI3K/AKT/mTOR agent that has shown encouraging tolerability without the high neutropenia rates seen in some IV regimens.</p>
<div class="lb-trans"><p>Naz Rahman 给予买入评级是基于与 paxalisib 相关的临床和市场背景的多种因素。他认为 Celcuity 在其 PI3K/mTOR 抑制剂的 III 期结果具有统计学显著性，这增强了对整个类别的信心，并进一步验证了 Kazia 采用的口服 PI3K/AKT/mTOR 药物的有效性，该药物在耐受性方面表现出令人鼓舞的结果，而没有一些静脉给药方案中观察到的高中性粒细胞减少率。</p>
</div><p>Rahman also notes that Celcuity’s pending PDUFA decision and growing deal activity in the PI3K/mTOR arena suggest rising strategic value for high-quality assets in this pathway. With Kazia expanding its triple-negative breast cancer trial and the broader mechanism being further de-risked, he has reduced his revenue risk assumptions for paxalisib and raised his 12‑month price target to $30, reinforcing his Buy recommendation on the stock.</p>
<div class="lb-trans"><p>Rahman 还指出，Celcuity 即将到来的 PDUFA 决策以及 PI3K/mTOR 领域日益增长的交易活动表明该路径中高质量资产的战略价值正在上升。随着 Kazia 扩大其三阴性乳腺癌试验以及更广泛的机制进一步降低风险，他降低了对 paxalisib 的收入风险假设，并将其 12 个月的目标价提高至 30 美元，进一步巩固了对该股票的买入推荐。</p>
</div><p>In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价为 18.00 美元。</p>
</div>

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

分析师将 Kazia 的目标价上调至 30 美元，并基于对 PI3K/AKT/mTOR 策略增强的信心，重申买入评级